Patents by Inventor Yoshiyuki Onishi
Yoshiyuki Onishi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10731159Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: November 22, 2019Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20200126464Abstract: A position/pose acquisition unit acquires a position and a pose of a viewpoint in a real space. A site data disposition unit disposes site data which is three-dimensional data representing a shape of a construction site in a virtual space on the basis of the position and the pose of the viewpoint. A machine data disposition unit disposes machine data which is three-dimensional data representing a shape of a work machine at a position corresponding to the site data in the virtual space. A rendering unit renders the disposed machine data.Type: ApplicationFiled: June 27, 2018Publication date: April 23, 2020Inventors: Yoshiyuki Onishi, Masahiro Kurihara
-
Publication number: 20200080086Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: November 22, 2019Publication date: March 12, 2020Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Publication number: 20200080080Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).Type: ApplicationFiled: December 25, 2017Publication date: March 12, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITYInventors: Kazumoto IIJIMA, Kandai NOZU, Akemi SHONO, Makoto KOIZUMI, Yoshiyuki ONISHI, Kiyosumi TAKAISHI, Tomomi ADACHI
-
Publication number: 20200074766Abstract: A work state identifying unit identifies work states of a work machine. A parameter identifying unit identifies a parameter related to a work amount per unit time of the work machine or a parameter related to a speed of the work machine for each of the identified work states on the basis of a time series of position data, azimuth data, or speed data of the work machine.Type: ApplicationFiled: June 26, 2018Publication date: March 5, 2020Inventors: Yoshiyuki Onishi, Shinya Kanou, Kyohei Kuroda, Shota Furukawa, Naoyuki Omuro
-
Publication number: 20200053321Abstract: An operation information transmission device transmits a state of each work medium performing work in a construction site (F) to an information providing device. The operation information transmission device includes an image data acquisition unit that acquires image data including the work medium, a type/state specifying unit that specifies the type and a state of the work medium included in the image data, and an operation information transmission unit that transmits operation information indicating the specified type and state of the work medium to the information providing device.Type: ApplicationFiled: June 27, 2018Publication date: February 13, 2020Inventor: Yoshiyuki Onishi
-
Patent number: 10533176Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: October 30, 2017Date of Patent: January 14, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Publication number: 20180374168Abstract: Provided is a simulation system capable of improving productivity in a construction site.Type: ApplicationFiled: March 30, 2017Publication date: December 27, 2018Inventors: Shinya Kano, Noriaki Kojima, Yoshiyuki Onishi, Kyohei Kuroda
-
Publication number: 20180051285Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: October 30, 2017Publication date: February 22, 2018Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Patent number: 9803199Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: GrantFiled: July 7, 2014Date of Patent: October 31, 2017Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
-
Patent number: 9662310Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: GrantFiled: February 3, 2015Date of Patent: May 30, 2017Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
-
Publication number: 20160257951Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.Type: ApplicationFiled: July 7, 2014Publication date: September 8, 2016Inventors: Makoto KOIZUMI, Yoshiyuki ONISHI, Takako NIWA, Masakazu TAMURA, Yuji KASUYA
-
Patent number: 9394235Abstract: An object of the present invention is to efficiently produce an optically active bicyclic compound. The optically active bicyclic compound is efficiently produced using an enzyme.Type: GrantFiled: October 10, 2014Date of Patent: July 19, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshitaka Nakamura, Yukito Furuya, Kousei Shimada, Yoshiyuki Onishi
-
Publication number: 20150216847Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: ApplicationFiled: February 3, 2015Publication date: August 6, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu NAGATA, Jun KOBAYASHI, Yoshiyuki ONISHI, Masamichi KISHIDA, Kengo NOGUCHI
-
Publication number: 20150038738Abstract: An object of the present invention is to efficiently produce an optically active bicyclic compound. The optically active bicyclic compound is efficiently produced using an enzyme.Type: ApplicationFiled: October 10, 2014Publication date: February 5, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshitaka Nakamura, Yukito Furuya, Kousei Shimada, Yoshiyuki Onishi
-
Patent number: 8946443Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: GrantFiled: March 14, 2011Date of Patent: February 3, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
-
Publication number: 20130035337Abstract: The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) ?. A compound having the general formula (I): wherein R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ?CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: March 13, 2012Publication date: February 7, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kousei Shimada, Yoshiyuki Onishi, Makoto Mori, Eri Tokumaru
-
Publication number: 20130012532Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: ApplicationFiled: March 14, 2011Publication date: January 10, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
-
Publication number: 20100048564Abstract: The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate or lipid metabolism or a disease mediated by peroxisome proliferator-activated receptor (PPAR) ?. A compound having the general formula (I): wherein R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; Q represents a group represented by the formula ?CH— or a nitrogen atom; and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 hydroxyalkyl group, and the like, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: October 5, 2009Publication date: February 25, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kousei SHIMADA, Yoshiyuki ONISHI, Makoto MORI, Eri TOKUMARU
-
Patent number: 4757185Abstract: An automatic cash transaction apparatus includes a circuit for performing signal reception and transmission with a card carried by a user through the medium of electromagnetic wave. When a number set in the card and received by the apparatus is authorized one, the user is allowed to input the type of transaction desired by the user, cipher number and other data as required through key manipulation, whereby the manual handling of the card is made unnecessary.Type: GrantFiled: April 27, 1987Date of Patent: July 12, 1988Assignee: Hitachi, Ltd.Inventor: Yoshiyuki Onishi